Integrated decision-tree testing strategies for mutagenicity and carcinogenicity with respect to the requirements of the EU REACH legislation

Alternatives to Laboratory Animals

Volumn 36, Issue SUPPL. 1, 2008, Pages 43-63

  Combes, Robert ^a   Grindon, Christina ^b   Cronin, Mark T D ^b   Roberts, David W ^b   Garrod, John F ^c  

^a RUSSELL AND BURCH HOUSE   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c DEFRA   (United Kingdom)

Author keywords

Animal testing; Carcinogenicity; Decision trees; Defra; Genotoxic carcinogens; In silico models; In vitro testing; Integrated testing strategies; Mutagenicity; Non genotoxic carcinogens; PBPK modelling; REACH; Risk assessment; Three Rs.

Indexed keywords

ANIMAL TESTING ALTERNATIVE; CARCINOGENICITY; CELL TRANSFORMATION; CHROMOSOME ABERRATION; COMPUTER MODEL; DNA DAMAGE; GENE EXPRESSION; GENE MUTATION; GENOTOXICITY; IN VITRO STUDY; MUTAGENICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICITY TESTING; TOXICOKINETICS;

ANIMALIA; RODENTIA;

EID: 57349180719     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290803601s05     Document Type: Note

References (128)

1. Anon. (2006). Defra Research Projects. Website http://www2.defra.gov.uk/research/project-data/more.asp?I=CB01067&M= KWS&V=reach&scope=0 (Accessed 01.03.06).
2. Grindon, C., Combes, R., Cronin, M.T.D., Roberts, D.W. & Garrod, J. (2006). A review of the status of alternative approaches to animal testing and the development of integrated testing strategies for assessing the toxicity of chemicals under REACH - a summary of a Defra-funded project conducted by Liverpool John Moores University and FRAME. ATLA 34, Suppl. 1, 149-158.
3. Grindon, C., Combes, R., Cronin, M.T.D., Roberts, D.W. & Garrod, J.F. (2006). Integrated testing strategies for use in the EU REACH system. ATLA 34, 407-427.
4. Knight, D.J. (2006). Intelligent approaches to safety evaluation. In Alternatives to Animal Testing, Issues in Environmental Science and Technology (ed. R.E. Hester & R.M. Harrison), pp. 74-94. Cambridge, UK: RSC Publishing.
5. Knight, D.J. & Thomas, M.B., eds (2003). Practical Guide to Chemical Safety Testing, 448pp. Shrewsbury, UK: Rapra Technology.
6. Combes, R.D. (1995). Regulatory genotoxicity testing: A critical appraisal. ATLA 23, 352-379.
7. Mitchell, I. de G. & Combes, R.D. (1997). In vitro genotoxicity and cell transformation assessment. In In Vitro Methods in Pharmaceutical Research (ed. J.V. Castell & M.J. Gómez-Lechón), pp. 318-352. London, UK & New York, NY, USA: Academic Press.
8. Combes, R.D. (1999). Mutagenicity. In Cosmetics: Controlled Efficacy Studies and Regulation (ed. P. Eisner, H. Merk & H.I. Mailbach), pp. 291-308. London, UK: Springer-Verlag.
9. Zeiger, E. (2001). Genetic toxicity tests for predicting carcinogenicity. In Genetic Toxicology and Cancer Risk Assessment (ed. W.N. Choy), pp. 29-46. New York, NY, USA: Marcel Dekker.
10. Anon. (1992). EEC Council Directive 92/32/EEC of 30 April 1992 amending for the 7th time Directive 67/548/EEC on the approximation of the laws, regulations and administration provisions relating to classification, packaging and labelling of dangerous substances. Official Journal of the European Union L154, 65-80.
11. Ashby, J., Waters, M.D., Preston, J., Adler, I-D., Douglas, G.R., Fielder, R., Shelby, M.D., Anderson, D., Sofuni, T., Gopalan, H.N., Becking, G. & Sonich-Mullin, C. (1996). IPCS harmonisation of methods for the prediction and quantification of human carcinogenic/mutagenic hazard, and for indicating the probable mechanism of action of carcinogens. Mutation Research 352, 153-157.
12. Combes, R.D. (1997). Statistical analysis of doseresponse data from in vitro assays: an illustration using Salmonella mutagenicity data. Toxicology in Vitro 11, 683-687.
13. Dillon, D., Combes, R. & Zeiger, E. (1998). The effectiveness of Salmonella strains TA100, TA102 and TA104 for detecting mutagenicity of some aldehydes and peroxides. Mutagenesis 13, 19-26.
14. Parry, E.M. & Parry, J.M. (1995). In vitro cytogenetics and aneuploidy. In Environmental Mutagenesis (ed. D.H. Phillips & S. Venitt), pp. 121-139. Oxford, UK: Bios Scientific Publishers.
15. Anon. (1997). Aneuploidy. ECETOC Monograph No. 27, 172pp. Brussels, Belgium: European Centre for Ecotoxicology and Toxicology of Chemicals.
16. Benigni, R., Passerini, L. & Rodomonte, A. (2003). Structure-activity relationships for the mutagenicity and carcinogencity of simple and alpha-beta unsaturated aldehydes. Environmental and Molecular Mutagenesis 42, 136-143.
17. Passerini, L. (2003). QSARs for individual classes of chemical mutagens and carcinogens. In Quantitative Structure-Activity Relationship (QSAR) Models of Mutagens and Carcinogens (ed. R. Benigni), pp. 81-123. Boca Raton FL, USA: CRC Press.
18. Benigni, R., ed. (2003). Quantitative Structure-Activity Relationship (QSAR) Models of Mutagens and Carcinogens, 304pp. Boca Raton FL, USA: CRC Press.
19. Vracko, M., Mills, D. & Basak, S.C. (2004). Structure-mutagenicity modelling using counter propagation neural networks. Environmental Toxicology and Pharmacology 16, 25-36.
20. Hawkins, D.M., Basak, S.C. & Mills, D. (2004). QSARs for chemical mutagens from structure: ridge regression fitting and diagnostics. Environmental Toxicology and Pharmacology 16, 37-44.
21. Votano, J.R., Parham, M., Hall, L.H., Kier, L.B., Oloff, S., Tropsha, A., Xie, Q.A. & Tong, W. (2004). Three new consensus QSAR models for the prediction of Ames genotoxicity. Mutagenesis 19, 365-377.
22. Klopman, G., Chakravarti, S.K., Harris, N., Ivanov, J. & Saiakhov, R.D. (2003). In silico screening of high production volume chemicals for mutagenicity using MCASE QSAR expert system. SAR and QSAR in Environmental Research 14, 165-180.
23. Klopman, G., Zhu, H., Fuller, M.A. & Saiakhov, R.D. (2004). Searching for an enhanced predictive tool for mutagenicity. SAR and QSAR in Environmental Research 15, 251-263.
24. Niemelå, J. & Wedebye, E. (2004). Evaluation of the Setubal Principles for Establishing the Status of Development and Validation of (Q)SARS. Annex 4: A "Global" Multi-Case Model for In Vitro Chromosomal Aberrations in Mammalian Cells. Website www.mst.dk/Kemi/Word/ work%20item% 201%20report-annex%204.doc (Accessed 16.10.06).
25. Gombar, V.K., Enslein, K., Hart, J.B., Blake, B.W. & Borgstedt, H.H. (1991). Estimation of maximum tolerated dose for long-term bioassays from acute lethal dose and structure by QSAR. Risk Analysis 11, 509-517.
26. Helma, C. (2005). In silico predictive toxicology: the state of the art and strategies to predict human health effects. Current Opinion in Drug Discovery & Development 8, 37-31.
27. Mekenyan, O., Dimitrov, S., Serafimova, R., Thompson, E., Kotov, S., Dimitrova, N. & Walker, J.D. (2004). Identification of the structural requirements for mutagenicity by incorporating molecular flexibility and metabolic activation of chemicals I: TA10 model. Chemical Research in Toxicology 17, 753-766.
28. Helma, C. (2006). Lazy structure-activity relationships (Lazar) for the prediction of rodent carcinogenicity and mutagenicity. Molecular Diversity 10, 147-158.
29. Ashby, J. & Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP. Mutation Research 257, 229-306.
30. Long, A. & Combes, R.D. (1995). Using DEREK to predict the activity of some carcinogens/mutagens found in foods. Toxicology in Vitro 9, 563-569.
31. Ridings, J.E., Barratt, M.D., Cary, R., Earnshaw, C.G., Eggington, C.E., Ellis, M.K., Judson, P.N., Langowski, J.J., Marchant, C.A., Payne, M.P., Watson, W.P. & Yih, T.D. (1996). Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. Toxicology 106, 267-279.
32. Combes, R.D. & Rodford, R.A. (2004). The use of expert systems for toxicity prediction: illustrated with reference to the DEREK program. In Predicting Chemical Toxicity and Fate (ed. M.T.D. Cronin & D.J. Livingstone), pp. 193-204. Boca Raton, FL, USA: CRC Press.
33. International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (1997). ICH Harmonised Tripartite Guideline: Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, 12pp. Geneva, Switzerland: ICH Secretariat. Website http://www.ich.org/pdflCH/s2b.pdf (Accessed 08.08.02).
34. Honma, M., Hayashi, M., Shimada, H., Tanaka, N., Wakuri, S., Awogi, T., Yamamoto, K.I., Kodan, N., Nishi, Y., Nakadate, M. & Sofuni, T. (1999). Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test. Mutagenesis 14, 5-52.
35. Cole, J., Harrington-Brock, K. & Moore, M.M. (1999). The mouse lymphoma assay in the wake of ICH4 - where are we now? Mutagenesis 14, 265-270.
36. Stopper, H. & Müller, S.O. (1997). Micronuclei as a biological endpoint for genotoxicity: A minireview. Toxicology in Vitro 11, 661-667.
37. Garriott, M.L., Phelps, J.B. & Hoffman, W.P. (2002). A protocol for the in vitro micronucleus test. I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity. Mutation Research 517, 123-134.
38. Kirsch-Volders, M., Sofuni, T., Aardema, M., Albertini, S., Eastmond, D., Fenech, M., Ishidate, M. Jr., Kirchner, S., Lorge, E., Morita, T., Norppa, H., Surralles, J., Vanhauwaert, A. & Wakata, A. (2003). Report from the in vitro micronucleus assay working group. Mutation Research 540, 153-163.
39. Phelps, J.B., Garriott, M.L. & Hoffman, W.P. (2002). A protocol for the in vitro micronucleus test. II. Contributions to the validation of a protocol suitable for regulatory submissions from an examination of 10 chemicals with different mechanisms of action and different levels of activity. Mutation Research 521, 103-112.
40. Aardema, M.J., Snyder, R.D., Spicer, C., Divi, K., Morita, T., Mauthe, R.J., Gibson, D.P., Soelter, S., Curry, P.T., Thybaud, V., Lorenzon, G., Marzin, D. & Lorge, E. (2006). SFTG international collaborative study on in vitro micronucleus test III. Using CHO cells. Mutation Research 607, 61-87.
41. Meintieres, S., Biola, A., Pallardy, M. & Marzin, D. (2003). Using CTLL-2 and CTLL-2 bcl2 cells to avoid interference by apoptosis in the in vitro micronucleus test. Environmental and Molecular Mutagenesis 41, 14-27.
42. Mirsalis, J.C. (1995). Assays for unscheduled DNA synthesis in vivo. In Environmental Mutagenesis (ed. D.H. Phillips & S. Vennitt), pp. 219-232. Oxford, UK: Bios Scientific Publishers.
43. Singh, N.P., McCoy, M.T., Tice, R.R. & Schneider, E.L. (1988). A simple technique for quantification of low levels of damage in individual cells. Experimental Cell Research 175, 184-191.
44. Tice, R.R., Agurell, E., Anderson, D., Burlinson, B., Hartmann, A., Kobayashi, H., Miyamae, Y., Rojas, E., Ryu, J.C. & Sasaki, Y.F. (2000). The single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis 35, 206-221.
45. Hartmann, A., Agurell, E., Beevers, C., Brendler-Schwaab, S., Burlinson, B., Clay, P., Collins, A., Smith, A., Speit, G., Thybaud, V. & Tice, R.R. (2003). Recommendations for conducting the in vivo alkaline Comet assay. Mutagenesis 18, 45-51.
46. McKelvey-Martin, V.I., Green, M.H.L., Schmezer, P., Pool-Zobel, B.L., DeMeo, M.P. & Collins, A. (1993). The single cell gel electrophoresis assay (Comet assay): a European perspective. Mutation Research 288, 47-63.
47. Tice, R.R. (1995). The single cell gel/Comet assay: microgel electrophoretic technique for the detection of DNA damage and repair in individual cells. In Environmental Mutagenesis (ed. D.H. Phillips & S. Venitt), pp. 315-339. Oxford, UK: Bios Scientific Publishers.
48. Anderson, D. & Plewa, M.J. (1998). The international Comet assay workshop. Mutagenesis 13, 67-73.
49. Crespi, C. (1995). Use of genetically engineered cells for genotoxicity testing. In Environmental Mutagenesis (ed. D.H. Phillips & S. Venitt), pp. 233-260. Oxford, UK: Bios Scientific Publishers.
50. Coecke, S., Ahr, H., Blaauboer, B.J., Bremer, S., Casati, S., Castell, J., Combes, R., Corvi, R., Crespi, C.L., Cunningham, M.L., Elaut, G., Eletti, B., Freidig, A., Gennari, A., Ghersi-Egea, J-F., Guillouzo, A., Hartung, T., Hoet, P., Ingelman-Sundberg, M., Munn, S., Jassens, W., Ladstetter, B., Leahy, D., Long, A., Meneguz, A., Monshouwer, M., Morath, S., Nagelkerke, F., Pelkonen, O., Ponti, J., Prieto, P., Richert, L., Sabbioni, E., Schaack, B., Steiling, W., Testai, E., Vericat, J-A. & Worth, A. (2006). Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM Workshop 54. ATLA 34, 49-84.
51. Aardema, M. & MacGregor, J.T. (2002). Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "omics" technologies. Mutation Research 499, 13-25.
52. Farr, S. & Dunn, R.T. (1999). Concise review: gene expression applied to toxicology. Toxicological Sciences 50, 1-9.
53. Anon. (2004). Joint Statement on the Use of Toxicogenomics in Toxicology. Committee on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Department of Health COT/04/10;COM/04/S5 & COC/04/S8, 6pp. London, UK: Department of Health.
54. Curren, R.D., Mun, G., Gibson, D.P. & Aardema, M.J. (2005). Development of a Novel Micronucleus Assay in the Human 3-D Skin Model, EpiDerm™. Presented at the 44th Annual Meeting of the Society of Toxicology New Orleans, Louisiana, March 6-10, 2005. Website http://66.102.9.104/search?q=cache: UL-0fbWBSM8J:www.iivs.org/documents/88.pdf+ micronucleus+induction+in+skin+cells&hl=en&gl=uk&ct=clnk&cd=3 (Accessed 16.10.06).
55. Dean, S.W., Brooks, T.M., Burlinson, B., Mirsalis, J., Myhr, B., Recio, L. & Thybaud, V. (1999). Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens. Mutagenesis 14, 141-151.
56. Nohmi, T., Suzuki, T. & Masumura, K. (2000). Recent advances in the protocols of transgenic mouse mutation assays. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 455, 191-215.
57. Dashwood, R.H. (2003). Use of transgenic and mutant animal models in the study of heterocyclic amine-induced mutagenesis and carcinogenesis. Journal of Biochemistry & Molecular Biology 36, 35-42.
58. Bhogal, N. & Combes, R.D. (2006). The relevance of genetically altered mouse models of human disease. ATLA 34, 429-454.
59. OECD (2005). Transgenic Rodent Mutation Assays. OECD Environment, Health and Safety Publications, Series on Testing and Assessment, Executive Summary, 5pp. Website www.oecd.org/dataoecd/39/28/34446478.pdf (Accessed 16.10.06). Paris, France: Organisation for Economic Co-operation and Development.
60. Gatehouse, D.G. & Tweats, D.J. (1986). Letter to the Editor. Mutagenesis 1, 307-308.
61. Ashby, J. (1986). Letter to the Editor. Mutagenesis 1, 309-317.
62. International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (1997). ICH Harmonised Tripartite Guideline. Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals S2B, Current Step 4 Version, dated 16 July 1997, 11pp. Website www.ich.org/LOB/media/MEDIA494.pdf (Accessed 16.10.06). Geneva, Switzerland: ICH.
63. Department of Health (2000). Guidance on a Strategy for Testing of Chemicals for Mutagenicity. Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment, 36pp. Website http://www.doh.gov.uk/com/ htm (Accessed 16.10.06).
64. Langley, G. (2001). The Way Forward - Action to End Animal Toxicity Testing, 36pp. London, UK: BUAV.
65. Worth, A.P. & Balls, M., eds (2002). Alternative (non-animal) methods for chemicals testing: current status and future prospects. A report prepared by ECVAM and the ECVAM Working Group on Chemicals. ATLA 30, Suppl. 1, 1-125.
66. Combes, R. & Balls, M. (2003). How much flexibility is possible when validating new in vivo and in vitro toxicity test methods? ATLA 31, 225-232.
67. Combes, R.D. (2000). The use of structure-activity relationships and markers of cell toxicity to detect non-genotoxic carcinogens. Toxicology in Vitro 14, 387.
68. Choy, W.N. (2001). Genotoxic and non-genotoxic mechanisms of carcinogenesis. In Genetic Toxicology and Cancer Risk Assessment (ed. W.N. Choy), pp. 47-72. New York, NY, USA: Marcel Dekker.
69. International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (1997). ICH Harmonised Tripartite Guideline. Testing for Carcinogenicity of Pharmaceuticals, Step 4 Report, 11pp. Geneva, Switzerland: ICH.
70. Cronin, M.T.D. & Dearden, J.C. (1995). QSAR in toxicology. 4. Prediction of non-lethal mammalian toxicological endpoints, and expert systems for toxicity prediction. Quantitative Structure-Activity Relationships 14, 518-523.
71. Cronin, M.T.D. & Dearden, J.C. (1995). QSAR in toxicology. 3. Prediction of chronic toxicities. Quantitative Structure-Activity Relationships 14, 329-334.
72. Patlewicz, G., Rodford, R. & Walker, J.D. (2003). Quantitative structure-activity relationships for predicting mutagenicity and carcinogenicity. Environmental Toxicology and Chemistry 22, 1885-1893.
73. Richard, A.M. & Benigni, R. (2002). AI and SAR approaches for predicting chemical carcinogenicity: Survey and status report. SAR and QSAR in Environmental Research 13, 1-19.
74. Helguera, A.M., Pérez, M.A.C., Combes, R. & González, M.P. (2005). The prediction of carcinogenicity from molecular structure. Current Computer-Aided Drug Design 1, 65-72.
75. Helguera, A.M., Pérez, M.A.C., Pérez González, M., Ruiz, R.M. & Diáz, H.G. (2005). A topological substructural approach applied to the computational prediction of rodent carcinogenicity. Bioorganic and Medicinal Chemistry 13, 2477-2488.
76. Benigni, R., Guiliani, A., Franke, R. & Gruska, A. (2000). Quantitative structure-activity relationships of mutagenicity and carcinogenic aromatic amines. Chemical Reviews 100, 3697-3714.
77. Passerini, L. (2003). QSARs for individual classes of chemical mutagens and carcinogens. In Quantitative Structure-Activity Relationship (QSAR) Models of Mutagens and Carcinogens (ed. R. Benigni), pp. 81-123. Boca Raton, FL, USA: CRC Press.
78. Helguera, A.M., Pérez, M.A.C., Combes, R. & Gonz-ález, M.P. (2006). Quantitative structure-activity relationship for the computational prediction of nitrocompounds carcinogenicity. Toxicology 220, 51-62.
79. Contrera, J.F., Matthews, E.J. & Benz, R.D. (2003). Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regulatory Toxicology and Pharmacology 38, 243-259.
80. Klopman, G., Chakravarti, S.K., Zhu, H., Ivanov, J.M. & Saiakhov, R.D. (2004). ESP: A method to predict toxicity and pharmacological properties of chemical using multiple MCASE databases. Journal of Chemical Information and Computer Science 44, 704-715.
81. Klopman, G., Ivanov, J., Saiakhov, R. & Chakravarti, S. (2005). MC4PC - An artificial intelligence approach to the discovery of quantitative structure-toxic activity relationships. In Predictive Toxicology (ed. C. Helma), pp. 423-457. Boca Raton FL, USA: CRC Press.
82. Matthews, E.J. & Contrera, J.F. (1998). A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regulatory Toxicology and Pharmacology 28, 242-264.
83. Woo, Y-T. & Lai, D.Y. (2005). OncoLogic: A mechanism-based expert system for predicting the carcinogenic potential of chemicals. In Predictive Toxicology (ed. C. Helma), pp. 385-413. Boca Raton FL, USA: CRC Press.
84. Combes, R D. & Balls, M. (2005). Intelligent testing strategies for chemicals testing - a case of more haste, less speed? ATLA 33, 289-297.
85. Benigni, R. (2004). Prediction of human health endpoints: mutagenicity and carcinogenicity. In Predicting Chemical Toxicity and Fate (ed. M.T.D. Cronin & D.J. Livingstone), pp. 173-192. Boca Raton FL, USA: CRC Press.
86. Combes, R., Balls, M., Curren, R., Fischbach, M., Fusenig, N., Kirkland, D., Lasne, C., Landolph, J., LeBoeuf, R., Marquardt, H., McCormick, J., Muller, L., Rivedal, E., Sabbioni, E., Tanaka, N., Vasseur, P. & Yamasaki, H. (1999). Cell transformation assays as predictors of human carcinogenicity. The report and recommendations of ECVAM Workshop 39. ATLA 27, 745-767.
87. OECD (2001). Detailed Review Paper on Non-Genotoxic Carcinogens Detection: The Performance of In Vitro Cell Transformation Assays. OECD Environment Health and Safety Publications, Series on Testing and Assessment, No. 31, 71pp. Paris, France: OECD Environment Directorate. Website http://www.oecd.org/dataoecd/58/29/1898492. pdf (Accessed 16.10.06).
88. Barrett, J.C., Kakanuga, T., Kuroki, T., Neubert, D., Trosko, J.E., Vasilieu, J.M., Williams, G.M. & Yamasaki, H. (1986). Mammalian cell transformation in culture. In Long and Short Term Test Assays for Carcinogens: A Critical Appraisal. IARC Scientific Publication No. 83 (ed. R. Monsanto, H. Bartsch, H. Vainio, J. Wilbourn & H. Yamasaki), pp. 267-286. Lyon, France; IARC.
89. Tsuchiya, T. & Umeda, M. (1995). Improvement in the efficiency of the in vitro transformation assay method using BALB/3T3 A31-1-1 cells. Carcinogenesis 16, 1887-1894.
90. Tsuchiya, T., Umeda, M., Nishiyama, H., Yoshimura, I., Ajimi, S., Asakura, M., Baba, H., Dewa, Y., Ebe, Y., Fushiwaki, Y., Hamada, S., Hamamura, T., Hayashi, M., Iwasa, Y., Kajiwara, Y., Ksahara, Y., Kawabata, M., Kitada, E., Kubo, K., Mashiko, K., Miura, D., Mizuhashi, F., Mizuno, F., Nakajima, M., Nakamura, Y., Nobe, N., Oishi, H., Ota, E., Sakai, A., Sato, M., Shimada, S., Sugiyama, T., Takahashi, C., Takeda, Y., Tanaka, N., Toyoizumi, C., Tsutsui, T., Wakuri, S., Yajima, S. & Yajima, N. (1999). An inter laboratory validation study of the improved transformation assay employing Balb/c 3T3 cells: results of a collaborative study on the two-stage cell transformation assay by the Nongenotoxic Carcinogen Study Group. ATLA 27, 685-702.
91. Reznikoff, T., Bertram, J.S., Brankow, D.W. & Heidelberger, C. (1973). Quantitative and qualitative studies on chemical transformation of cloned C3H mouse embryo cells sensitive to post-confluence inhibition of cell division. Cancer Research 33, 3239-3249.
92. Landolph, R.A. (1985). Chemical transformation in C3H10T1/2 CC118 mouse embryo fibroblasts: historical background, assessment of transformation assay and evolution and optimization of the transformation assay protocol. In Transformation assay of established cell lines: Mechanisms and Application, IRAC Scientific Publications No. 67 (ed. T. Kakunaga & H. Yamasaki), pp. 185-203. Lyon, France: IRAC.
93. LeBoeuf, R.A., Kerckaert, K.A., Aardema, M.J. & Isfort, R.J. (1999). Use of Syrian hamster embryo and Balb/c 3T3 cell transformation for assessing the carcinogenicity potential of chemicals. In The Use of Short- and Medium-term Tests for Carcinogenic Hazard Evaluation, IRAC Scientific Publications No. 146 (ed. D.B. McGregor, J.M. Rice & S. Venitt), pp. 409-425. Lyon, France: IRAC.
94. Sasaki, K., Mizusawa, H., & Ishidate, M. (1988). Isolation and characterization of ras-transfected BALB/3T3 clone showing morphological transformation by 12-O-tetradecanoylphorbol-13-acetate. Japanese Journal of Cancer Research 79, 921-930.
95. Sasaki, K., Mizusawa, H., Ishidate, M. & Tanaka, N. (1990). Transformation of ras transfected BALB 3T3 clone (Bhas 42) by promoters: Application for screening and specificity of promoters. Toxicology in Vitro 4, 657-659.
96. Stuard, S.B., Kerckaert, G.A. & Lehman-McKeeman, L.D. (1999). Characterisation of the metabolic capacity of Syrian hamster embryo (SHE) cells. Toxicological Sciences 48, 366.
97. Toraason, M., Bohrman, J.S., Krieg, E., Combes, R.D., Willington, S.E., Zajac, W. & Langenbach, R. (1992). Evaluation of the V79 cell metabolic cooperation assay as a screen for developmental toxicants. Toxicology in Vitro 6, 165-174.
98. Rivedal, E., Mikalsen, S.O. & Sanner, T. (2000). Morphological transformation and effect on gap junction intercellular communication in Syrian hamster embryo cells as screening tests for carcinogens devoid of mutagenic activity. Toxicology in Vitro 14, 185-192.
99. Blaha, L., Kapplova, P., Vondracek, J., Upham, B. & Machala, M. (2002). Inhibition of gap-junctional intercellular communication by environmentally occurring polycyclic aromatic hydrocarbons. Toxicological Sciences 65, 43-51.
100. Vosseler, S., Mirancea, N., Bohlen, P., Mueller, M.M. & Fusenig, N.E. (2005). Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalises stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Research 65, 1294-1305.
101. Sanyal, S. (2006). In Vitro Models for Studying Angiogenesis. Website www.display-product.htangiogeneisismodel.htm (Accessed 16.10.06).
102. Kozien, D., Gerol, M., Hendey, W. & RayChaudhury, A. (2000). A novel in vitro model of tumor angiogenesis. In Vitro Cellular & Developmental Biology - Animal 36, 555-558.
103. Mueller, M.M. & Fusenig, N.E. (2002). Tumorstroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 70, 486-497.
104. Chishima, T., Yang, M., Miyagi, Y., Li, L., Tan, Y., Baranov, E., Shimada, H., Moossa, A.R., Penman, S. & Hoffman, R.M. (1997). Governing step of metastatis visualized in vitro. Proceedings of the National Academy of Sciences of the USA 94, 11573-11576.
105. Tennant, R.W., French, J.E. & Spalding, J.W. (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environmental Health Perspectives 103, 942-950.
106. van Zeller, A-M. & Combes, R.D. (1999). Transgenic mouse bioassays for carcinogenicity testing: a step in the right direction? ATLA 27, 839-846.
107. Battershill, J.M. & Fielder, R.J. (1998). Mousespecific carcinogens: An assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice. Human and Experimental Toxicology 17, 193-205.
108. Blain, P.G., Battershill, J.M., Venitt, S., Cooper, C.C. & Fielder, R.J. (1998). Consideration of shortterm carcinogenicity tests using transgenic mouse models. Mutation Research 403, 259-263.
109. Cohen, S.M., Robinson, D. & MacDonald, J. (2001). Alternative models for carcinogenicity testing. Toxicological Sciences 64, 14-17.
110. Knight, A.J., Bailey, J. & Balcombe, J. (2006). Animal carcinogenicity studies. 3. Alternatives to the bioassay. ATLA 34, 39-48.
111. Combes, R.D., Anderson, D., Brooks, T., Neale, S. & Venitt, S. (1984). The detection of mutagens in urine, faeces and body fluids. In Guidelines for Mutagenicity Testing, Part II, Supplementary Tests, Mutagens in Body Fluids and Excreta, Nitrosation Products (ed. B.J. Dean), pp. 203-244. Swansea, UK: United Kingdom Environmental Mutagen Society.
112. Gaylor, D.W. & Zheng, Q. (1996). Risk assessment of non-genotoxic carcinogens based upon cell proliferation/death rates in rodents. Risk Analysis 16, 221-225.
113. Kirkland, D., Aardema, M., Henderson, L. & Muller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens: I. Sensitivity, specificity and relative predictivity. Mutation Research 584, 1-256.
114. Gatehouse, D. (1987). Critical features of bacterial mutation assays. Mutagenesis 2, 397-409.
115. Hastwell, P.W., Chai, L-L., Roberts, K.J., Webster, T.W., Harvey, J.S., Rees, R.W. & Walmsley, R.M. (2006). High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen® HC GADD45a-GFP genotoxicity assay. Mutation Research 607, 160-175.
116. Cahill, P.A, Knight, A.W., Billinton, N., Barker, M.G., Walsh, L., Keenan, P.O., Williams, C.V., Tweats, D.J. & Walmsley, R.M. (2004). The GreenScreen® genotoxicity assay: a screening validation programme. Mutagenesis 19, 105-119.
117. Van Gompel, J., Woestenborghs, F., Beerens, D., Mackie, C., Cahill, P.A., Knight, A.W., Billinton, N., Tweats, D.J. & Walmsley, R.M. (2005). An assessment of the utility of the yeast GreenScreen® assay in pharmaceutical screening. Mutagenesis 20, 449-154.
118. PETA (2006). Creative Accounting - (Mis)udging the Costs and Benefits of Rodent Cancer Studies by the UK Home Office. 32pp. Website http://www.peta.org.uk/feat/cancertests.asp (Accessed 16.10.06). London, UK: People for the Ethical Treatment of Animals, UK.
119. Knight, A., Bailey, J. & Balcombe, J. (2005). Animal carcinogenicity studies - poor human predictivity. ATLA 34, 19-27.
120. Knight, A., Bailey, J. & Balcombe, J. (2005). Animal carcinogenicity studies - obstacles to human extrapolation. ATLA 34, 29-38.
121. Combes, R.D., Gaunt, I. & Balls, M. (2004). A scientific and animal welfare assessment of the OECD Health Effects Test Guidelines for the safety testing of chemicals under the European Union REACH system. ATLA 32, 163-208.
122. Combes, R.D. (2006). The OECD Health Effects Test Guidelines for REACH need updating. ALTEX 23 Special Issue 124-130.
123. Criswell, K.A., Krishna, G., Zielinski, D., Urda, G.A., Juneau, P., Bulera, S. & Bleavins, M.R. (2003). Validation of a flow cytometric acridine orange micronuclei methodology in rats. Mutation Research 528, 1-18.
124. Torous, D.K., Hall, N.E., Murante, F.G., Gleason, S.E., Tometsko, C.R. & Dertinger, S.D. (2003). Comparative scoring of micronucleated reticulocytes in rat peripheral blood by flow cytometry and microscopy. Toxicological Sciences 74, 309-314.
125. Richard, A.M. & Williams, C.R. (2003). Public sources of mutagenicity and carcinogenicity data: use in structure-activity relationship models. In QSARs of Mutagens and Carcinogens (ed. R. Benigni), pp. 152-178. London, UK: CRC Press.
126. Pedersen, F., de Bruijn, J., Munn, S. & van Leeuwen, K. (2003). Assessment of Additional Testing Needs under REACH. Effects of QSARs, Risk Based Testing and Voluntary Industry Initiatives. Report EUR 20863, 36pp. Ispra, Italy: European Commission, Joint Research Centre.
127. Johannsen, F.R. (1990). Risk assessment of carcinogenic and non-carcinogenic chemicals. Critical Reviews in Toxicology 20, 341-367.
128. Combes, R.D. (2005). Assessing risk to humans from chemical exposure by using non-animal test data. Toxicology in Vitro 19, 921-924.